Today's stock news 08/06/2026: ALK-Abelló
Summary
- ALK-Abelló has launched the nasal adrenaline spray neffy® 2 mg in Canada, following Health Canada's approval in April 2026.
- The product is the first needle-free adrenaline treatment for anaphylaxis, targeting adults and children weighing 30 kg or more.
- Canada is expected to become ALK's largest market outside Europe, with up to 2.5 million citizens affected by severe allergies.
- The launch does not alter ALK's financial guidance for 2026.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in undefined 06/08/2026, 06:11 GMT. Give feedback here.
ALK-Abelló (ALK) announced yesterday that the company is now launching the nasal adrenaline spray neffy® 2 mg in Canada following approval from Health Canada in April 2026. The needle-free product is the first adrenaline treatment in spray form for anaphylaxis and will make it easier for both adults and children (≥30 kg) to act quickly in severe allergic reactions. Canada is set to become ALK's largest market outside Europe, with up to 2.5 million citizens affected by severe allergies. A smaller 1 mg dose for children (15-30 kg) is still awaiting regulatory review and could further expand the target group. neffy® was developed by US-based ARS Pharma, for which ALK holds global commercial rights outside Australia, New Zealand, Japan, and China, as well as a co-promotion agreement in the USA. The launch does not change the company's guidance for 2026. Read the full announcement here: https://www.inderes.dk/releases/market-launch-of-the-nasal-adrenaline-spray-neffyr-for-treatment-of-adults-and-children-with-severe-allergies-in-canada
Disclaimer: HC Andersen Capital receives payment from the mentioned companies for a Digital IR subscription agreement. /William Jørck on 08/06/2026 at 08:10 AM.